Right ventricular pulmonary hypertension

Current Heart Failure Reports

Volumn 9, Issue 4, 2012, Pages 303-308

  Guazzi, Marco ^a   Castelvecchio, Serenella ^a   Bandera, Francesco ^b   Menicanti, Lorenzo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b IRCCS POLICLINICO SAN DONATO   (Italy)

Author keywords

Heart failure; Pulmonary hypertension; Right ventricle

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; PROSTAGLANDIN; SILDENAFIL;

ARTICLE; CARDIAC PATIENT; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR RISK; DISEASE SEVERITY; DRUG EFFICACY; ENZYME INHIBITION; HEART DILATATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART RIGHT VENTRICLE EJECTION FRACTION; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE HYPERTROPHY; HEART SURGERY; HUMAN; LEFT VENTRICULAR ASSIST DEVICE; LUNG VASCULAR RESISTANCE; NONHUMAN; PULMONARY HYPERTENSION; RISK ASSESSMENT;

HEART FAILURE; HUMANS; HYPERTENSION, PULMONARY; RISK ASSESSMENT; VENTRICULAR DYSFUNCTION, RIGHT;

EID: 84872174844     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-012-0106-8     Document Type: Article

References (58)

1. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. ESC Committee for Practice Guidelines (CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30:2493-537.
2. Guazzi M, Arena R. Pulmonary hypertension with left-sided heart disease. Nat Rev Cardiol. 2010;7:648-59. Extensive literature revision on the epidemiology and pathophysiology and clinical impact of left-sided PH.
3. Lam CS, Borlaug BA, Kane GC, Enders FT, Rodeheffer RJ, Redfield MM. Age-Associated increases in pulmonary artery systolic pressure in the general population. Circulation. 2009;119:2663-70. Peculiar demonstration that ageing may be associated with an abnormal increase in PASP, a condition that powerfully predicts survival as compared to reference echo-derived prognosticators, such as LV mass, left atrial volume index and E/E'
4. Miller WL, Mahoney DW, Michelena HI, Pislaru SV, Topilsky Y, Enriquez-Sarano M. Contribution of ventricular diastolic dysfunction to pulmonary hypertension complicating chronic systolic heart failure. J Am Coll Cardiol Img. 2011;4:946-54.
5. Bursi F, McNallan SM, Redfield MM, Nkomo VT, Lam CS, Weston SA, et al. Pulmonary pressures and death in heart failure: a community study. J Am Coll Cardiol. 2012;59:222-31.
6. Leung CC, Moondra V, Catherwood E, Andrus BW. Prevalence and risk factors of pulmonary hypertension in patients with elevated pulmonary venous pressure and preserved ejection fraction. Am J Cardiol. 2010;106:284-6.
7. Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol. 2009;53:1119-26.
8. De Groote P, Millaire A, Foucher-Hossein C, et al. Right ventricular ejection fraction is an independent predictor of survival in patients with moderate heart failure. J Am Coll Cardiol. 1998;32: 948-54.
9. Di Salvo TG, Mathier M, Semigran MJ, Dec WG. Preserved right ventricular ejection fraction predicts exercise capacity and survival in advanced heart failure. J Am Coll Cardiol. 1995;25:1143-53.
10. Ghio S, Gavazzi A, Campana C, et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol. 2001;37:183-8. Landmark observations showing that the presence of RV dysfunction has important implications for risk stratification in Group 2 PH above and beyond pulmonary pressures. (Pubitemid 32051736)
11. Desai RV,Meyer P, AhmedMI,MujibM,Adamopoulos C,WhiteM, et al. Relationship between left and right ventricular ejection fractions in chronic advanced systolic heart failure: insights from the BEST trial. Eur J Heart Fail. 2011;13:392-7.
12. Gavazzi A, Berzuini C, Campana C, Inserra C, Ponzetta M, Sebastiani R, et al. Value of right ventricular ejection fraction in predicting shortterm prognosis of patients with severe chronic heart failure. J Heart Lung Transpl. 1997;16:774-85.
13. Meyer P, Filippatos GS, Ahmed MI, Iskandrian AE, Bittner V, Perry GJ, et al. Effects of right ventricular ejection fraction on outcomes in chronic systolic heart failure. Circulation. 2010;121:252-8.
14. Ghio S, Recusani F, Klersy C, Sebastiani R, Laudisa ML, Campana C, et al. Prognostic usefulness of the tricuspid annular plane systolic excursion in patients with congestive heart failure secondary to idiopathic or ischemic dilated cardiomyopathy. Am J Cardiol. 2000;85:837-42.
15. Damy T, Kallvikbacka-Bennett A, Goode K, Khaleva O, Lewinter C, Hobkirk J, et al. Prevalence of, Associations with, and Prognostic Value of Tricuspid Annular Plane Systolic Excursion (TAPSE) among out-patients referred for the evaluation of heart failure. J Card Fail. 2012;18:216-25.
16. D'Andrea A, Gravino R, Riegler L, Salerno G, Scarafile R, Romano M, et al. Right ventricular ejection fraction and left ventricular dyssynchrony by 3D echo correlate with functional impairment in patients with dilated cardiomyopathy. J Card Fail. 2011;17:309-17.
17. Lewis GD, Shah RV, Pappagianopolas PP, Systrom DM, Semigran MJ. Determinants of ventilatory efficiency in heart failure: the role of right ventricular performance and pulmonary vascular tone. Circ Heart Fail. 2008;1:227-33.
18. Murphy RM, Shah RV, Malhotra R, Pappagianopoulos PP, Hough SS, Systrom DM, et al. Exercise oscillatory ventilation in systolic heart failure: an indicator of impaired hemodynamic response to exercise. Circulation. 2011;124:1442-51.
19. Champion HC, Michelakis ED, Hassoun PM. Comprehensive invasive and noninvasive approach to the right ventricle-pulmonary circulation unit: state of the art and clinical and research implications. Circulation. 2009;120:992-1007.
20. Saouti N, Westerhof N, Postmus PE, Vonk-Noordegraaf A. The arterial load in pulmonary hypertension. Eur Respir Rev. 2010;19:197-203. Remarkable overview on pulmonary arterial/right ventricular coupling.
21. Lankhaar JW, Westerhof N, Faes TJ, Gan CT, Marques KM, Boonstra A, et al. Pulmonary vascular resistance and compliance stay inversely related during treatment of pulmonary hypertension. Eur Heart J. 2008;29:1688-95.
22. Tedford RJ, Hassoun PM, Mathai SC, Girgis RE, Russell SD, Thiemann DR, et al. Pulmonary capillary wedge pressure augments right ventricular pulsatile loading. Circulation. 2012;17:289-97.
23. Urashima T, Zhao M, Wagner R, et al. Molecular and physiological characterization of RV remodeling in a murine model of pulmonary stenosis. Am J Physiol Heart Circ Physiol. 2008;295:H1351-68.
24. Bogaard HJ, Natarajan R, Henderson SC, Long CS, Kraskauskas D, Smithson L, et al. Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure. Circulation. 2009;120:1951-60. Very elegant demonstration that RV remodeling may be somewhat independent of hemodynamic load comparing an experimental model of pulmonary artery banding with an established model of angioproliferative pulmonary hypertension associated with fatal RV failure.
25. LaVecchia L, Zanolla L,Varotto L, Bonanno C, SpadaroGL,Ometto R, et al. Reduced right ventricular ejection fraction as a marker for idiopathic dilated cardiomyopathy compared with ischemic left ventricular dysfunction. Am Heart J. 2001;142:181-9. (Pubitemid 32595392)
26. Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009;53:589-96.
27. Dini FL, Demmer RT, Simioniuc A, Morrone D, Donati F, Guarini G, et al. Right ventricular dysfunction is associated with chronic kidney disease and predicts survival in patients with chronic systolic heart failure. Eur J Heart Fail. 2012;14:287-94.
28. Dickstein K, Cohen-Solal A, Filippatos G,McMurray JJ, Ponikowski P, Poole-Wilson PA, et al. ESC Committee for Practice Guidelines (CPG). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29:2388-442.
29. Voelkel NF, Quaife RA, Leinwand LA, et al. Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation. 2006;114:1883-91.
30. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation. 1992;85:504-9.
31. Wada A, Tsutamoto T, Fukai D, Ohnishi M, Maeda K, Hisanaga T, et al. Comparison of the effects of selective endothelin ETA and ETB receptor antagonists in congestive heart failure. J Am Coll Cardiol. 1997;30:1385-92.
32. Kalra PR, Moon JC, Coats AJ. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol. 2002;85:195-7. (Pubitemid 35245980)
33. Packer M, McMurray J, Massie BM, Caspi A, Charlon V, Cohen-Solal A, et al. Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J Card Fail. 2005;11:12-20.
34. Lüscher TF, Enseleit F, Pacher R, Mitrovic V, Schulze MR, Willenbrock R, et al. Heart Failure ET(A) Receptor Blockade Trial. Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT). Circulation. 2002;106:2666-72.
35. Anand I, McMurray J, Cohn JN, Konstam MA, Notter T, Quitzau K, et al. EARTH investigators. Long-Term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364:347-54.
36. Yui Y, Nakajima H, Kawai C, Murakami T. Prostacyclin therapy in patients with congestive heart failure. Am J Cardiol. 1982;50:320-4. (Pubitemid 12059027)
37. Sablotzki A, Czeslick E, Schubert S, Friedrich I, Mühling J, Dehne MG, et al. Iloprost improves hemodynamics in patients with severe chronic cardiac failure and secondary pulmonary hypertension. Can J Anaesth. 2002;49:1076-80.
38. Califf RM, Adams KF, McKenna WJ, Gheorghiade M, Uretsky BF,McNulty SE, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1997;134:44-54.
39. Argenziano M, Choudhri AF, Moazami N, Rose EA, Smith CR, Levin HR, et al. Randomized, double-blind trial of inhaled nitric oxide in LVAD recipients with pulmonary hypertension. Ann Thorac Surg. 1998;65:340-5. (Pubitemid 28083325)
40. Kieler-Jensen N, Ricksten SE, Stenqvist O, Bergh CH, Lindelöv B, Wennmalm A, et al. Inhaled nitric oxide in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance. J Heart Lung Transplant. 1994;13:366-75.
41. Bocchi EA, Bacal F, Auler Júnior JO, Carmone MJ, Bellotti G, Pileggi F. Inhaled nitric oxide leading to pulmonary edema in stable severe heart failure. Am J Cardiol. 1994;74:70-2. (Pubitemid 24196320)
42. Miller OI, Tang SF, Keech A, Celermajer DS. Rebound pulmonary hypertension on withdrawal from inhaled nitric oxide. Lancet. 1995;346:51-2.
43. Guazzi M. Clinical use of phophodiesterase-5 inhibitors in chronic heart failure. Circ Heart Fail. 2008;1:272-80.
44. Guazzi M, Tumminello G, Di Marco F, Fiorentini C, Guazzi MD. The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. J Am Coll Cardiol. 2004;44:2339-48.
45. Melenovsky V, Al-Hiti H, Kazdova L, Jabor A, Syrovatka P, Malek I, et al. Transpulmonary B-Type natriuretic peptide uptake and cyclic guanosine monophosphate release in heart failure and pulmonary hypertension: the effects of sildenafil. J Am Coll Cardiol. 2009;54:595-600.
46. Guazzi M, Samaja M, Arena R, Vicenzi M, Guazzi MD. Long-Term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol. 2007;50:2136-44.
47. Lewis GD, Shah R, Shahzad K, Camuso JM, Pappagianopoulos PP, Hung J, et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation. 2007;116:1555-62.
48. BehlingA, Rohde LE, Colombo FC, Goldraich LA, Stein R, Clausell N. Effects of 5'-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial. J Card Fail. 2008;14:189-97.
49. Nagendran J, Archer SL, Soliman D, Gurtu V, Moudgil R, Haromy A, et al. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation. 2007;116:238-48.
50. Yin J, Kukucka M, Hoffmann J, Sterner-Kock A, Burhenne J, Haefeli WE, et al. Sildenafil preserves lung endothelial function and prevents pulmonary vascular remodeling in a rat model of diastolic heart failure. Circ Heart Fail. 2011;4:198-206.
51. Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation. 2011;124:164-74.
52. Telford RJ, Hemnes AR, Russel SD, Wittstein IS, Mahmud M, Zaiman AL, et al. PDE5 inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support. Circ. Heart Fail. 2008;1:213-9.
53. Bleeker GB, Schalij MJ, Nihoyannopoulos P, Steendijk P, Molhoek SG, van Erven L, et al. Left ventricular dyssynchrony predicts right ventricular remodeling after cardiac resynchronization therapy. J Am Coll Cardiol. 2005;46:2264-9. (Pubitemid 41785495)
54. Haddad H, Elabbassi W, Moustafa S, et al. Left ventricular assist device as bridge to heart transplantation in congestive heart failure with pulmonaryhypertension. ASAIO J. 2005;51:456-60.
55. Zimpfer D, Zrunek P, Sandner S, et al. Posttransplant survival after lowering fixed pulmonary hypertension using left ventricular assist devices. Eur J Cardiothorac Surg. 2007;31:698-702.
56. Patel ND, Weiss ES, Schaffer J, et al. Right heart dysfunction after left ventricular assist device implantation: a comparison of the pulsatile HeartMate I and axial-flow HeartMate II devices. Ann Thorac Surg. 2008;86:832-40.
57. Menicanti L, Castelvecchio S. Left ventricular reconstruction concomitant to coronary artery bypass grafting: when and how? Curr Opin Cardiol. 2011;26:523-7.
58. Patel ND, Williams JA, Nwakanma LU, Waldron MM, Bluemke DA, Conte JV. Surgical ventricular restoration for advanced congestive heart failure: should pulmonary hypertension be a contraindication? Ann Thorac Surg. 2006;82:879-88.